HANGZHOU, China, Sept. 26, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ('Jo-Jo Drugstores' or the 'Company'), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that it has entered into definitive agreements with a number of investors providing for the issuance of 9.96 million ordinary shares, at a purchase price of $0.26 per share (the 'Purchase Price'), in a registered direct offering for aggregate gross proceeds of approximately $2.59 million.

中国杭州，2023年9月26日/PRNewswire/-中国Jo Jo Drugstores，Inc。（纳斯达克股票代码：CJJD）（'Jo-Jo Drugstores'或'公司'），一家领先的在线和离线零售商，中国药品及其他保健产品和保健提供者批发经销商，今天宣布，它已与一些投资者签订了明确的协议，规定以每股0.26美元的购买价格（“购买价格”）发行996万股普通股，注册直接发行总额约为259万美元。

Jo-Jo Drugstores also agreed to issue to the investors registered warrants to purchase up to 19.92 million ordinary shares. The warrants will have a term of three years, be exercisable immediately at the Purchase Price. The closing of the sale of the securities is expected to occur on or about September 28, 2023, subject to satisfaction of customary closing conditions..

Jo Jo Drugstores还同意向注册认股权证的投资者发行，以购买多达1992万股普通股。认股权证期限为三年，可立即以购买价格行使。根据习惯性结业条件的满足，证券销售的结业预计将于2023年9月28日或左右进行。。

Jo-Jo Drugstores intends to use the net proceeds from the offering for general corporate purposes and working capital. The ordinary shares and warrants described above are being offered pursuant to a 'shelf' registration statement on Form F-3 (File No. 333-259692), which was declared effective by the United States Securities and Exchange Commission (the 'SEC') on December 19, 2022.

Jo Jo Drugstores打算将该产品的净收益用于一般公司用途和营运资本。上述普通股及认股权证是根据美国证券交易委员会（「证券交易委员会」）宣布生效的表格F-3（档案编号333-259692）的「架子」登记声明提供的。2022年12月19日。

The ordinary shares and warrants described above may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. When filed with the SEC, copies of the final prospectus supplement and the accompanying prospectus relating to the registered direct offering may be obtained at the SEC's website at http://www.sec.gov..

上述普通股及认股权证只能通过IPO说明书（包括IPO补编）提供，构成有效登记声明的一部分。在向美国证券交易委员会提交时，可以在美国证券交易委员会的网站上获取最终IPO补充说明和随附的与注册直接发行有关的IPO说明书的副本http://www.sec.gov..

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不得构成出售或征求购买报价的提议，也不得在任何州或管辖区销售这些证券，在注册或资格之前此类报价，征求或销售将是非法的根据任何此类州或管辖区的证券法。。

About China Jo-Jo Drugstores, Inc.

关于中国Jo Jo Drugstores，Inc。

China Jo-Jo Drugstores, Inc. ('Jo-Jo Drugstores' or the 'Company'), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours.

中国Jo Jo Drugstores，Inc。（'Jo-Jo Drugstores'或'公司'）是中国领先的在线和离线零售商和制药及其他医疗产品批发分销商以及医疗服务提供商。Jo Jo Drugstores目前在网上设有在线药房和零售药店，并在现场为有执照的医生提供咨询，检查和治疗常见疾病的时间。

It is also a wholesale distributor of products similar to those carried in its pharmacies. For more information about the Company, please visit http://jiuzhou360.com. The Company routinely posts important information on its website..

它也是与其药房相似的产品批发经销商。有关公司的更多信息，请访问http://jiuzhou360.com.公司经常在其网站上发布重要信息。。

Forward-Looking Statements

前瞻性声明

This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property.

本新闻稿包含有关公司对其未来期望，计划和前景的看法的信息，这些信息构成前瞻性声明。实际结果可能与历史结果或这些前瞻性陈述所表明的结果有很大不同，原因有多种因素，包括但不限于与其筹集额外资金的能力相关的风险和不确定性，维持和发展业务的能力，运营结果的可变性，维护和提升品牌的能力，其新产品和服务的开发和引入，收购公司，技术和资产成功整合到其产品和服务组合中，营销和其他业务开发计划，行业竞争，一般政府监管，经济条件，对关键的依赖人员，吸引能力，雇用和留住具备满足客户要求所需技术技能和经验的人员，以及保护其知识产权的能力。

The Company's encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission..

本公司鼓励您在本公司的年度报告及其与证券交易委员会的其他文件中审查可能影响其未来结果的其他因素。。

For more information, please contact:

欲了解更多信息，请联系：

Company Contact: Frank ZhaoChief Financial Officer+86-571-88077108[email protected]

公司联系人：Frank Zhao首席财务官+86-571-88077108[电子邮件保护]

Investor Relations Contact:Tina XiaoAscent Investor Relations LLC+1- 646-932-7242[email protected]

投资者关系联系人：Tina XiaoAscent Investor Relations LLC+1-646-932-7242[电子邮件保护]

SOURCE China Jo-Jo Drugstores, Inc.

资料来源中国Jo Jo Drugstores，Inc。